XML 37 R25.htm IDEA: XBRL DOCUMENT v3.21.2
License Revenue with 3D Medicines, Inc. (Tables)
6 Months Ended
Jun. 30, 2021
Revenue from Contract with Customer [Abstract]  
Deferred Revenue, Related to Upfront Cash Payment Received
The following table presents a summary of the activity in the Company's deferred revenue, related to the total cash payments received of $9.5 million to date under the 3DMed License, during the six months ended June 30, 2021 (in thousands):

December 31, 2020AdditionsRevenue RecognizedJune 30, 2021
Deferred revenue$5,600 $2,000 $(7,600)$—